Generics 1

Originals

Biosimilars

Medical devices

Nutraceuticals

Filters

Idebenone manufacturers

1 products found

Filters

Filters

Filters , active

Country of origin : Argentina

Clear all

1 products found

idebenone

Tablets, film coated 30mg, 45mg

Dossier type
CTD
Dossier status
Ready to file
Country of origin
Argentina
GMP approvals
Argentina
Available for
Distribution only
Manufacturer #16240
It is a laboratory that produces several product lines, such as allergy, cardiology, clinic, dermatology, gastroenterology, geriatrics, neurology, pediatrics, psychiatry, and urology, among others.

Manufacturer usually replies in 6 days

Want to see all 1 products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

IDEBENONE

Idebenone is used in the treatment and manages Alzheimer's, Huntington’s, liver, and heart diseases. It also treats some inherited disorders including Leber’s hereditary optic neuropathy, mitochondrial encephalomyopathies that involve nerve and muscle disorders, Duchenne muscular dystrophy, and Friedreich's ataxia, a nervous system disorder producing gait and speech problems, and eventually leading toward heart disease and diabetes. Idebenone is similar to coenzyme Q-10 and a man-made product. Idebenone is sold under brand names Catena, Raxone, Sovrima, among others. Takeda Pharmaceutical Company initially developed it for the treatment of Alzheimer's disease and other cognitive defects but met with limited success. Later, Santhera Pharmaceuticals, a Swiss co investigated it for the treatment of neuromuscular diseases. In 2010, It was tested for Friedreich's ataxia and Duchenne muscular dystrophy but it was not approved for the above in North America or Europe. In 2007, Idebenone was approved by the European Medicines Agency for use in Leber's hereditary optic neuropathy and received its designation as an orphan drug.

Dosage and administration

Idebenone is sold as tablets in 300mg strength and taken orally. In the treatment of Alzheimer's disease, the recommended initial adult dose is 90-120 mg, taken three times a day. In treating inherited Leber's hereditary optic neuropathy, the dose is 300 mg, taken orally three times per day with meals for both children and adults. In children, in the treatment of Duchenne muscular dystrophy, the dose is 900 mg, taken daily for one year.

The price of Idebenone

In the international market, a supply of 20mg of for the ingredient form costs around USD 247. In India, the consumers have to pay a retail price of USD 2.8 for a supply of 10 tablets of 45mg strength.

How does it work?

Idebenone has several actions, some of the actions include stimulation of ATP formation, increasing the antioxidant capacity, scavenging the free radicals, protecting against lipid peroxidation. It also bypasses the dysfunctional complex I of the mitochondrial respiratory chain.

Finding Idebenone Manufacturers and Suppliers:

The process of finding trusted Idebenone manufacturers and Idebenone suppliers can be made quicker and more accessible by using Pipelinepharma's online platform, a B2B marketplace that lets you finalize the deals of pharmaceutical products in a matter of a few clicks. In addition, it is an easy-to-use online platform to grow your business opportunities. The robust search engine makes it convenient to search for manufacturers and suppliers of Idebenone. The search can be further refined with industry-specific filters such as dossier type, country of origin, GMP approvals, and search criteria for Wholesaler, etc. helping to get in contact with the preferred manufacturer and supplier readily.

Interested in becoming a subscriber?

Please provide the following information to receive an offer tailored to your business needs

  1. Number of company users for the subscription
  2. The rough number of products you would like to source in the 12 months
  3. Target market(s) for commercialisation